BioSpace News Archive

Phagelux, Inc., a clinical-stage ready biotechnology company focused on the discovery and development of bacteriophages and lysins to treat and prevent antibiotic resistant infections, today announced that it has scheduled a company presentation at Biotech Showcase 2020

Duke University Hospital has transported its first donor heart using the only commercially available FDA cleared and CE marked system for cold donor heart storage and transport.

VBI Vaccines Inc. reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B vaccine, and comparing safety and immunogenicity of Sci-B-Vac® to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B®.

Aspect Biosystems (“Aspect”) (“the Company”), a biotechnology company pioneering microfluidic 3D bioprinting of human tissues, today announced a US $20 million Series A financing round.

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it has initiated enrollment in its Phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration

Marrone Bio (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced a $13.0 million expansion of its existing accounts-receivable credit facility which now totals $20.0 million, as well as the addition of a $3.0 million inventory-backed credit facility to support the Company as it continues to expand its customer base.

ChemoCentryx, Inc., announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc., a leader in customized financing for companies in life sciences and technology-related markets.

IntraOp Medical Corporation announced today that Alliant Dermatology in The Villages, Florida has commenced treating skin cancer patients with its latest technology—a Mobetron® electron beam linear accelerator optimized to treat skin lesions.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the promotion of Thomas Hoover to the newly created position of Chief Commercial Officer.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.